<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04505397</url>
  </required_header>
  <id_info>
    <org_study_id>SKL24741C001</org_study_id>
    <nct_id>NCT04505397</nct_id>
  </id_info>
  <brief_title>Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study of SKL24741 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Life Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spaulding Clinical Research LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SK Life Science, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates SKL24741 safety and tolerability in healthy subjects. Subjects will be&#xD;
      randomized to receive oral capsules of SKL24741 or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the curve (AUC) of SKL24741 after a single and multiple doses of SKL24741</measure>
    <time_frame>18 Months</time_frame>
    <description>Safety Assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum plasma concentration (Cmax) after a single and multiple doses of SKL24741</measure>
    <time_frame>18 months</time_frame>
    <description>Safety Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety - adverse events (AEs) reporting after a single and multiple doses of SKL24741</measure>
    <time_frame>18 months</time_frame>
    <description>Adverse event assessment for seriousness (yes, no), severity (mild, moderate, severe), affect on SKL24741 dosing (increase, reduced, interrupted, withdrawn, no change), and outcome (recovered/resolved,recovered/resolved with sequelae, recovering/resolving, not recovered/not resolved, fatal or unknown).</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 10 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 25 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 50 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 100 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 200 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 300 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 400 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 600 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 800 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Ascending Dose Level 10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 Subjects will receive one dose of 1000 mg and 2 subjects will receive one dose of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Subjects will receive one dose each day for 14 days and 2 subjects will receive one dose placebo every day for 14 days. The dose will be determined by the outcome of the Single Ascending Dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKL24741</intervention_name>
    <description>There will be a single dose escalation to analyze safety and tolerability. Once a dose is selected based on data from the single dose, a gender effect and food effect cohort will enroll followed by a multiple ascending dose escalation study.</description>
    <arm_group_label>Multiple Ascending Dose Level 1</arm_group_label>
    <arm_group_label>Multiple Ascending Dose Level 2</arm_group_label>
    <arm_group_label>Multiple Ascending Dose Level 3</arm_group_label>
    <arm_group_label>Multiple Ascending Dose Level 4</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 1</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 10</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 2</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 3</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 4</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 5</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 6</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 7</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 8</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic SKL24741</description>
    <arm_group_label>Multiple Ascending Dose Level 1</arm_group_label>
    <arm_group_label>Multiple Ascending Dose Level 2</arm_group_label>
    <arm_group_label>Multiple Ascending Dose Level 3</arm_group_label>
    <arm_group_label>Multiple Ascending Dose Level 4</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 1</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 10</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 2</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 3</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 4</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 5</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 6</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 7</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 8</arm_group_label>
    <arm_group_label>Single Ascending Dose Level 9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects of 18 to 50 years of age (inclusive)&#xD;
&#xD;
          2. Able to read, understand, sign, and date a written informed consent form (ICF) before&#xD;
             study participation at screening&#xD;
&#xD;
          3. Agree to use 2 highly effective methods of contraception, including at least one&#xD;
             barrier method (Section 10.6.7 for details)&#xD;
&#xD;
          4. Body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening&#xD;
&#xD;
          5. Judged to be in good health on the basis of medical history, physical examination, and&#xD;
             routine laboratory measurements (i.e., without clinically relevant pathology)&#xD;
&#xD;
          6. Normal electrocardiogram (ECG) (12-lead), arterial blood pressure, and heart rate&#xD;
             within the normal range of the study center or considered not clinically significant&#xD;
             by the investigator and in agreement with the Sponsor&#xD;
&#xD;
          7. Able to understand and comply with protocol requirements and instructions and likely&#xD;
             to complete the study as planned&#xD;
&#xD;
          8. For Part A (gender effect cohort): Female of non-childbearing potential (18 to 50&#xD;
             years of age (inclusive)), who have undergone a sterilization procedure at least 6&#xD;
             months prior to dosing with official documentation (e.g., hysteroscopic sterilization,&#xD;
             bilateral tubal ligation or bilateral salpingectomy, hysterectomy, or bilateral&#xD;
             oophorectomy), or be postmenopausal with amenorrhea for at least 1 year prior to&#xD;
             dosing and follicle-stimulating hormone (FSH) serum levels consistent with&#xD;
             postmenopausal status as per Principal Investigator's judgment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. History of any illness or condition that, in the opinion of the investigator, might&#xD;
             confound the results of the study or pose an additional risk in administering study&#xD;
             drug to the subjects 2. Smokers (subjects who have smoked within 6 months at screening&#xD;
             or those with positive results from smoking screening) 3. Cholecystectomy and/or&#xD;
             surgery of the gastrointestinal tract that could interfere with pharmacokinetics of&#xD;
             the trial medication (except appendectomy and simple hernia repair).&#xD;
&#xD;
             4. Regular treatment with prescription medications. Subjects should have ended any&#xD;
             prescription medications at least 14 days before the first dosing of the study drug.&#xD;
             Potential subjects should only stop any prescribed medication at the direction of a&#xD;
             physician.&#xD;
&#xD;
             5. Regular treatment with nonprescription medications. Subjects should have ended any&#xD;
             nonprescription medications at least 14 days before the first dosing of the study&#xD;
             drug. Potential subjects should consult a physician before stopping any regular&#xD;
             treatment with nonprescription medication.&#xD;
&#xD;
             6. Consumption of herbal medications, dietary supplements, and specific fruit&#xD;
             products. Subjects should have stopped consumption of herbal medications or dietary&#xD;
             supplements (e.g., St. John's Wort, ginkgo biloba, and garlic supplements), vitamins,&#xD;
             and grapefruit or grapefruit juice, or Seville oranges at least 14 days before the&#xD;
             first dosing of study drug.&#xD;
&#xD;
             7. History of drug or alcohol abuse or addiction within 2 years before the start of&#xD;
             study drug dosing, or a positive test results for alcohol or drugs of abuse, such as&#xD;
             amphetamine, barbiturate, benzodiazepine, cocaine, methadone, opiates, oxycodone,&#xD;
             phencyclidine, propoxyphene, cannabinoid (THC), MDMA (Ecstasy), methaqualone, and&#xD;
             tricyclic antidepressant (TCA).&#xD;
&#xD;
             8. Regular consumption of more than 2 units of alcoholic beverages per day or more&#xD;
             than 14 units per week (1 unit of alcohol equals 1 pint [473 mL] of beer or lager, 1&#xD;
             glass [125 mL] of wine, 25 mL shot of 40% spirit) before screening. Subjects may not&#xD;
             consume any alcohol from 72 hours before the first dosing of study drug through the&#xD;
             completion of the last PK sampling.&#xD;
&#xD;
             9. Consumption of an average of more than 5 servings (8 ounces per serving) per day of&#xD;
             coffee, cola, or other caffeinated beverage before screening. Subjects may not consume&#xD;
             any caffeinated beverages from 48 hours prior to dosing until the collection of the&#xD;
             last PK sample.&#xD;
&#xD;
             10. Participation in a clinical study involving administration of either an&#xD;
             investigational or a marketed drug within 2 months or 7 half-lives (whichever is&#xD;
             longer) before screening.&#xD;
&#xD;
             11. Blood donation or a significant loss of blood within 60 days of the start of study&#xD;
             drug dosing or donation of more than 1 unit of plasma within 7 days before screening.&#xD;
&#xD;
             12. Positive result at screening for any of the following infectious disease tests:&#xD;
             hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV Ab), human&#xD;
             immunodeficiency virus antigen and antibody (HIV Ag, HIV Ab) 13. Illness within 5 days&#xD;
             before the start of study drug dosing (&quot;illness&quot; is defined as an acute [serious or&#xD;
             non-serious] condition [e.g., the flu or the common cold]) 14. History of any known&#xD;
             relevant allergy/hypersensitivity (including allergy to the trial medication or its&#xD;
             excipients) 15. Subject who is judged not eligible for study participation by&#xD;
             investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study will enroll 92 Healthy Male Subjects and 6 Non-childbearing potential Female Subjects.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caitlin Stacom</last_name>
    <phone>201-421-3839</phone>
    <email>cstacom@sklsi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jimmy Schiemann, MD</last_name>
    <phone>201-431-8768</phone>
    <email>jschiemann@sklsi.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spaulding Clinical Research</name>
      <address>
        <city>West Bend</city>
        <state>Wisconsin</state>
        <zip>53095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jody Hammonds</last_name>
      <phone>262-365-5403</phone>
      <email>jody.hammonds@spauldingclinical.com</email>
    </contact>
    <investigator>
      <last_name>Carlos Sanabria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>January 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>September 3, 2020</last_update_submitted>
  <last_update_submitted_qc>September 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT04505397/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

